JIan-gong Wang

Prof. JIan-gong Wang


Research Focus & Metrics

Representative Publications

View All Publications
5 May 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
YLYi‐Hui Li
Yi‐Hui Li
YZYang Zhou
Yang Zhou
YLYuan‐Yuan Liu
Yuan‐Yuan Liu
GZGuang‐Ju Zhang
Guang‐Ju Zhang
LXLei Xiao
Lei Xiao
LZLi Zhang
Li Zhang
Immune checkpoint inhibitors (ICIs) have achieved prominent efficacy in the treatment of numerous cancers, which is the most significant breakthrough in cancer therapy in recent years. However, ICIs are associated with a series of immune‐related adverse events (irAEs). Pneumonitis is an uncommon but potentially fatal irAE. In the case reported here, a patient with advanced small cell lung cancer (SCLC) had rapid progression of disease following chemotherapy and received ICIs. The patient experienced severe immune‐related hyperthermia followed by immune‐related pneumonitis. Fortunately, a good clinical response was achieved after the patient received corticosteroids and tocilizumab.

9 September 2022 in Medicine
Verified
Journal Article
Open access
YLYi-Hui Mmed Li
Yi-Hui Mmed Li
YZYang Zhou
Yang Zhou
GZGuang-Ju Mmed Zhang
Guang-Ju Mmed Zhang
YWYu-Wei Mmed Wang
Yu-Wei Mmed Wang
JWJIan-gong Wang
JIan-gong Wang
YLYufeng Li
Yufeng Li
Rationale: Vulvar melanoma is a rare and aggressive tumor with a high risk of local recurrence and distant metastasis. The prognosis is poor with a 5-year overall survival rate of only 46.6%. Management of vulvar melanoma remains a clinical challenge. Recent evidences have shown that immune checkpoint inhibitors are effective in the treatment of vulvar melanoma. Patient concerns and diagnoses: A 63-year-old woman with vulvar malignant melanoma suffered inguinal lymph node metastasis after vulvectomy and chemotherapy. She underwent inguinal lymph node dissection and inguinal radiotherapy. The tumor progressed again and she received immunotherapy. Interventions: The tumor progressed again, and she was admitted to our hospital and received toripalimab combined with apatinib and abraxane. Outcomes: After 6 cycles of immunotherapy, the efficacy achieved partial remission. And with toripalimab as maintenance therapy, the patient achieved durable antitumor efficacy and good safety. Lessons: In this rare case, the patient with metastatic vulvar malignant melanoma had durable antitumor efficacy and good safety when receiving toripalimab.

Verified
Open access
媛媛媛刘 媛
媛刘 媛
慧义慧李 义
慧李 义
JWJIan-gong Wang
JIan-gong Wang
肺癌是全球死亡率最高的癌种。第一、二代表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs)的出现,在一定程度上极大地提高了非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的生存期及生活质量,但大多数患者在经过一段时间的无进展生存期后会产生耐药性,其中以T790M突变为主要耐药机制。针对此耐药突变出现的是以奥希替尼为代表的第三代EGFR-TKIs,其效果显著,然而仍不可避免的出现耐药性,如:C797S突变、间质表皮转化(mesenchymal-epithelial transition, MET)、RAS突变、BRAF突变、小细胞肺癌(small cell lung cancer, SCLC)转化、上皮间质细胞转化(epithelial mesenchymal transition, EMT)等。但是目前第三代EGFR-TKIs耐药后并没有标准有效的治疗方案。故本文主要阐述三代后的新一代EGFR-TKIs的研究进展,为后续的研究及治疗提供一定的参考。